반응식
[O:1]=[C:2]1[N:6]([C:7]2[CH:17]=[CH:16][C:10]([C:11]([O:13]CC)=O)=[CH:9][CH:8]=2)[CH2:5][CH2:4][O:3]1.[CH3:18][C:19]1[C:24]([N:25]2[CH2:30][CH2:29][NH:28][CH2:27][CH2:26]2)=[CH:23][CH:22]=[C:21]([CH3:31])[N:20]=1>>[CH3:18][C:19]1[C:24]([N:25]2[CH2:30][CH2:29][N:28]([C:11]([C:10]3[CH:9]=[CH:8][C:7]([N:6]4[CH2:5][CH2:4][O:3][C:2]4=[O:1])=[CH:17][CH:16]=3)=[O:13])[CH2:27][CH2:26]2)=[CH:23][CH:22]=[C:21]([CH3:31])[N:20]=1참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Example 34 and using ethyl 4-(2-oxooxazolidin-3-yl)benzoate (353 mg) described in Preparation Example 12 and 1-(2,6-dimethylpyridin-3-yl)piperazine (287 mg) described in Preparation Example 153, the title compound (90.2 mg) was obtained.
후처리
- customBy reaction and treatment in the same manner as in Example 34
- customdescribed in Preparation Example 153
출처 및 근거
- ORD 기록
- ord-2f016fdd0c174f72b85a00e4faed29d4
- 출처 데이터셋
- uspto-grants-2013_01
- 특허 번호
- US08354401B2
연결된 노트
불러오는 중…